D&D Pharmatech (XKRX:347850) YoY EBITDA Growth : -70.88% (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. D&D Pharmatech's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was -70.88%.

D&D Pharmatech's EBITDA per Share for the three months ended in Mar. 2025 was ₩-780.94.

D&D Pharmatech YoY EBITDA Growth Historical Data

The historical data trend for D&D Pharmatech's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D&D Pharmatech YoY EBITDA Growth Chart

D&D Pharmatech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

-286.92

-1.79

-141.68

106.07

-315.95

D&D Pharmatech Quarterly Data
	Dec18	Dec19	Dec20	Dec21	Dec22	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial								96.77	-238.99	-654.82	-621.97	-70.88

D&D Pharmatech YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

D&D Pharmatech's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(-2388.335	-	1105.971)	/	\| 1105.971 \|
=	-315.95 %

D&D Pharmatech's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(-780.939	-	-457.023)	/	\| -457.023 \|
=	-70.88 %

D&D Pharmatech YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

D&D Pharmatech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR

Website

http://www.ddpharmatech.com

D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech Headlines

No Headlines